| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2017-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108623691-B |
| titleOfInvention |
IgG (immunoglobulin G) -like long-acting immune fusion protein and application thereof |
| abstract |
The invention discloses an IgG sample long-acting immune fusion protein and application thereof. The IgG-like long-acting immune fusion protein provided by the invention consists of an effector molecule and an IgG antibody constant region, wherein the effector molecule is connected with the IgG antibody constant region through a connecting peptide; the effector molecule is a protein capable of exerting physiological functions in vivo; the IgG antibody constant region is a structure of the IgG antibody without two heavy chain variable regions and two light chain variable regions. The IgG-like immune fusion protein provided by the invention can effectively prolong the biological half-life of protein drugs (effector molecules) on the premise of ensuring higher affinity and better in-vivo activity with target molecules, and is far better than similar Fc immune fusion proteins. The IgG-like long-acting immune fusion protein provided by the invention can be used for treating various diseases such as diabetes, tumor, autoimmune disease, endocrine and the like. |
| priorityDate |
2017-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |